Authors
Latest:
Dr Dholaria on the Use of Liso-Cel in Relapsed/Refractory CLLBhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.
Latest:
Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert DermatopathologistPhyu Aung, MD, PhD, FCAP, a dermatopathologist, discusses key challenges in diagnosing and treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Definitive diagnosis is difficult given BPDCN’s heterogeneous features and frequent skin and CNS involvement. Recent advances have utilized immunophenotyping and targeted CD123, which is overexpressed on BPDCN cells. However, resistance develops with CD123 monotherapy. She notes that while testing aids BPDCN insights, more prognostic markers are needed, and emphasizes that continued cross-disciplinary research is critical to better outcomes.
Latest:
Dr Murciano-Goroff on the Evaluation of LY3537982 in KRAS G12C–Mutated NSCLC, CRC and Other Solid TumorsYonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the evaluation of LY3537982 in patients with KRAS G12C–mutated non–small cell lung cancer, colorectal cancer, and other solid tumors.
Latest:
Gifts from Walther, Regenstrief Foundations Create Cancer Informatics Chair at IU Simon Comprehensive Cancer CenterGifts totaling $3 million will create an endowed chair in cancer informatics at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Latest:
Fellows Can Join the Fight Against Cancer Misinformation OnlineMany cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.
Latest:
Dr. Bahary on the Benefits of Ivosidenib in IDH1-Mutated CholangiocarcinomaNathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.
Latest:
Dr. Facciabene on Radiation Bridging Therapy Prior to CAR T-Cell Therapy in Mice ModelsAndrea Facciabene, PhD, discusses investigating the use of bridging radiation therapy prior to CAR T-cell therapy in mice models.
Latest:
Dr. Carrizosa on the Prevalence of NRG1 Gene Fusions in Solid TumorsDaniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.
Latest:
Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate CancerSarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.
Latest:
A New Take on Preclinical Drug Trials for Glioblastoma TreatmentThe Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to change the way preclinical studies are developed and conducted to assess the efficacy of drugs for glioblastoma multiforme.
Latest:
Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor TypesAnita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.
Latest:
Novel Therapies for R/R Follicular LymphomaA panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.
Latest:
Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL AmyloidosisEfstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.
Latest:
Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid TumorsTimothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.
Latest:
Dr Ludmir on the Rationale For the EXTEND Trial in PDACEthan B. Ludmir, MD, shares the rationale for and the outcomes derived from the EXTEND trial in oligometastatic pancreatic ductal adenocarcinoma.
Latest:
Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCCYousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.
Latest:
Understanding How to Best Measure MRD Negativity in Ph+ ALLThe implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.
Latest:
Optimizing Therapy for Patients with Advanced Bladder CancerAli R. Khaki, MD, comments on how to treat patients with advanced bladder cancer based on data demonstrated by the EV-103 study of enfortumab vedotin.
Latest:
Slow Burn to Wildfire: How Do We Douse the Flames of Burnout in Oncology?Trauma and stress related to the COVID-19 pandemic, coupled with subsequent widespread labor shortages, have turned burnout, which was an endemic issue in medicine, to a pandemic in health care.
Latest:
Future Directions in Precision Medicine: An Evolving Treatment LandscapeClosing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.
Latest:
INDIGO: A Phase 3 Global, Randomized, Double-Blinded Study of Vorasidenib vs Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 MutationTimothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.
Latest:
The Evolving Treatment Landscape of Small Cell Lung CancerClosing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Latest:
Dato-DXd vs Docetaxel in Previously Treated Advanced/Metastatic Non–Small Cell Lung Cancer: Results of the Randomized Phase III Study TROPION-Lung01Aaron Lisberg, MD, reviews data from the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.
Latest:
Incorporating Treatment Advances Into mRCC ManagementExpectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
Latest:
Dr. Khan on the Rationale of Examining Disparate Outcomes in GI Tract Cancer SurgerySajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.
Latest:
The Evolving Field of GVHD TreatmentSophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.
Latest:
Dr Bupathi on Updates in the Second-Line Management of Advanced RCCManojkumar Bupathi, MD, MS, discusses updates in the second-line management of metastatic renal cell carcinoma and anticipated research in this space.
